Vendor Intelligence Report: Mix Peptides

Executive summary

Mix Peptides is not a broad-catalog story; it is a narrow GLP-1 dossier with uneven vial-level risk. Across 34 Finnrick lab tests, Mix Peptides has 24 passes and 10 failures — an overall pass rate of 71%. Retatrutide is the relatively better-tested choice, but still carries early contamination history; Tirzepatide is the weaker read, anchored by a no-batch overfill event and prior cross-peptide mixing. Ratings also contract under stricter fill and purity methods, which matters for buyers dosing from the label.

The business surface is atypical even for gray-market peptides. Mix operates through Discord and GLP-1 Forum rather than a stable storefront; the active domain resolves to a private WordPress login, while a natural no-hyphen lookalike is parked and unresolved. Order instructions documented crypto-only rails, no US-registered legal entity was identified, and the two public operators are handle-linked rather than legal-name-linked.

The supply-chain file gives this report its bite. A factory-notified recall places Mix as a reseller supplied by an unidentified manufacturer, and public COA verification attempts did not resolve for the Janoshik IDs reviewed. The dossier also separates service reputation from product reliability: forum reviews describe fast domestic fulfillment and responsive support, while lab evidence shows batch-segregation and fill-accuracy failures.

For buyers already evaluating Mix, the directional take is not a simple safe-or-unsafe verdict. Retatrutide with exact-batch confirmation is the more defensible of the two tested products; Tirzepatide, especially unlabeled/no-batch or historical high-strength lots, is the product requiring the most caution. The full report shows batch evidence, channel-authentication anchors, and supply-chain comparisons for deciding whether a specific vial path is worth the risk.

Inside the full report:

• Per-product pass/fail rates and methodology-divergence charts for both tested products
• Tirzepatide and Retatrutide exhibits for the overfill, recall, and recovery pattern
• Ham001 and u/lana0183 operator-handle provenance analysis
• RDAP, DNS, hosting, WordPress-login, and Discord-invite authentication map
• Factory-control, COA-verification, domestic-fulfillment, and JEEP-comparison findings

Risk assessment

• Tirzepatide quality and dosing-risk — high: Tirzepatide: 23 tests (16 pass / 7 fail), 72.25%; a no-batch T30 vial tested 51.1mg (+70.3%), and T60 batch 2025A512-09 was tied to Retatrutide contamination.
• Retatrutide quality risk — high: Retatrutide: 11 tests (8 pass / 3 fail), 77.11%; early R30 batch 2025B56-09 was part of the peptide-mixing recall, though later tests improved.
• Factory-control and supply-chain transparency risk — high: The Chinese factory is unidentified; the October 2025 recall was factory-notified, batch-code semantics are unresolved, and cited Janoshik COAs could not be publicly verified.
• Corporate accountability and buyer-recourse risk — high: No US-registered legal entity was identified; ordering is Discord/forum-based and payments are crypto-only, limiting recourse after a failed or mis-shipped batch.
• Operator-identity opacity risk — medium: Ham001 and u/lana0183 are linked operational handles, but real names, ownership, and formal roles remain unverified.
• Channel-authentication and platform-stability risk — medium: Discord invites have rotated after expiry, crash, and reported attack; the official domain is private and the no-hyphen lookalike is parked, complicating authenticity checks.